JP2003073278A - Anti-helicobacter pylori agent - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an anti-helicobacter pylori agent by which large degerming effect against helicobacter pylori can be obtained under physiolosical conditions (under acidic conditions) without requiring use of an antibiotic, a composition having other degerming effect or a gastric inhibitory agent and the degerming effect can further be enhanced by combined use of an antibiotic and/or lactic acid and an agent for preventing onset, relapse or recrudescence of gastritis, stomach ulcer or duodenal ulcer containing the anti-helicobacter pylori agent and a food for preventing gastritis, stomach ulcer or duodenal ulcer containing the anti-helicobacter pylori agent. SOLUTION: This anti-helicobacter pylori agent comprises a steryl glucopyranoside and/or its derivative as an active ingredient.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to an anti-Helicobacter pylori agent containing steryl glucopyranoside and / or a derivative thereof as an active ingredient, which has a bactericidal action, particularly a strong bactericidal action against Helicobacter pylori, and an antibiotic and / Or by using in combination with lactic acid, an anti-Helicobacter pylori agent that can further enhance the sterilization effect, further gastritis containing the anti-Helicobacter pylori agent, onset or recurrence of gastric ulcer or duodenal ulcer, relapse preventive agent, and The present invention relates to a food or drink for preventing gastritis, gastric ulcer or duodenal ulcer containing an anti-Helicobacter pylori drug.

[0002]

[Related Technology] Helicobacter pylori was introduced in 1983 by Warren JR and Marshall BJ.
(Lancet, 1273-1275 (1983)), which was isolated from the gastric mucosa of patients with chronic gastritis. Helicobacter pylori is a Gram-negative bacillus that lives under microaerobic conditions, has a strong urease activity, acts on urea in food to synthesize ammonia, and neutralizes the strongly acidic gastric acid of pH 1-2. In this way, the living environment is adjusted and it is possible to live in the gastric mucosa. It is estimated that gastric mucosa is injured and inflammation or ulcer occurs due to ammonia or physiologically active substances secreted by Helicobacter pylori, and as a cure and prevention of gastritis, gastric ulcer, and duodenal ulcer, eradication of Helicobacter pylori has attracted attention in recent years. ing.

As a method for erasing Helicobacter pylori, various methods such as antibiotics, Chinese herbs and food ingredients have been studied. Helicobacter pylori is ampicillin,
Although it is sensitive to antibiotics such as tetracycline, erythromycin, penicillin, and clarithromycin, administration of the antibiotic alone does not show sufficient antibacterial action. It is considered that this is because the antibacterial activity of antibiotics is reduced by gastric acid, and the bacterial cells acquire drug resistance. Currently, as the eradication therapy for Helicobacter pylori, two of antibiotics such as bismuth drug, tetracycline drug, penicillin drug, cephalosporin drug, macrolide drug, quinolone drug, and nitroimidazole drug, or A method that uses three agents together,
A combination therapy with a proton pump inhibitor (PPI), which is a gastric acid secretion inhibitor, and two antibiotics is common.

However, these antibacterial therapies have various problems such as a large amount and frequency of administration, side effects such as diarrhea and constipation, and development of resistant bacteria. A compound having a strong antibacterial activity is desired.

[0005]

In view of the above-mentioned state of the art, the present inventors have searched for a compound having a strong antibacterial action against Helicobacter pylori, and have found a compound having a strong antibacterial action under acidic conditions. Heading, completed the present invention.

The present invention does not require the use of antibiotics or other compositions having a bactericidal effect, or the use of gastric acid secretion inhibitors,
An anti-Helicobacter pylori that can obtain a large sterilizing effect against Helicobacter pylori even under physiological conditions (acidic conditions), and can further enhance the sterilizing effect by combined use with an antibiotic and / or lactic acid. The present invention provides a food and drink for preventing gastritis, gastric ulcer or duodenal ulcer, which further comprises an anti-Helicobacter pylori drug, gastritis, gastric ulcer or duodenal ulcer onset or recurrence, and an anti-recurrence agent, and the anti-Helicobacter pylori drug. The purpose is to

[0007]

In order to solve the above problems, the anti-Helicobacter pylori agent of the present invention contains steryl glucopyranoside and / or its derivative as an active ingredient. As the steryl glucopyranoside, a compound selected from the group consisting of cholesteryl glucopyranoside, sitosteryl glucopyranoside, stigmastereryl glucopyranoside, campesteryl glucopyranoside and brassicasteryl glucopyranoside can be used alone or in combination.

The above-mentioned steryl glucopyranoside is a substance in which various sterols and glucose are bound to each other by α- or β-glucopyranoside, and is universally present in higher plants. In animals and bacteria, mycobacteria and candida are used. , Spiroplasma, true slime mold, and Helicobacter are known to exist, but their functions have not been clarified yet.

In the genus Helicobacter, three kinds of cholesteryl glucopyranoside (Cholesteryl glucopyranoside: C
G), that is, cholesteryl-α-D-glupyranoside (CGL, hereinafter also referred to as α-cholesteryl glucopyranoside or α-CG), cholesteryl-6-O-tetradecanoyl-α. -D-glucopyranoside (Cholesteryl-6-O-te
tradecanoyl-α-D-glucopyranoside (CAG) and cholesteryl-6-O-phosphatidyl-α-D-glucopyranoside (Cholesteryl-6-O-phosphatidyl-α-D-glu).
The existence of copyranoside (CPG) has been reported (J. B.
acterol, 177, 5334-5337 (1995), J. Bacterol, 178,
2065-2070 (1996), J. Bacterol, 177, 5327-5333 (199
Five)). Many naturally occurring glucopyranoside bonds are β-forms, whereas only α-forms are found in Helicobacter.

Steryl glucopyranoside (Steryl g) which is an active ingredient in the anti-Helicobacter pylori agent of the present invention
As lucopyranoside), cholesteryl glucopyranoside (Cholesteryl glucopyranoside), sitosteryl glucopyranoside (Sitosteryl glucopyranoside), stigmasteryl glucopyranoside (Stigmasteryl glucopyranoside)
ide), Campesteryl glucopyranoside (Campesteryl g
lucopyranoside), and brassicasteryl glucopyranoside). Although some isomers of the present compound exist, any of the isomers may be used, and the glucopyranoside bond may be of α-form or β-form and is not limited in the present invention.

However, in terms of pharmacological activity, α-cholesteryl glucopyranoside found in Helicobacter pylori exhibits a superior effect.

Derivatives which can be easily converted into the above steryl glucopyranoside can also be used as the active ingredient of the anti-Helicobacter pylori agent according to the present invention. As the above derivative, an acylated derivative of steryl glucopyranoside, for example, an acylated glucopyranoside in which the 6-position of the glucose moiety is esterified can be preferably used. Hereinafter, the steryl glucopyranoside and / or its derivative will be referred to as steryl glucopyranoside.

By adding an antibiotic and / or lactic acid to the anti-Helicobacter pylori agent containing the above-mentioned steryl glucopyranoside as an active ingredient, the combined effect, that is, the bactericidal effect can be further enhanced.

The anti-Helicobacter pylori agent according to the present invention can be used as an agent for preventing the onset or recurrence of gastritis, gastric ulcer or duodenal ulcer, or relapse by administration alone or together with an ordinary pharmaceutical carrier.

Further, by incorporating the anti-Helicobacter pylori agent according to the present invention into foods and drinks, for example, fermented milk such as yogurt, lactic acid bacteria beverages, powdered foods, granular foods, paste-like foods, etc., to eradicate Helicobacter pylori. Alternatively, it can be used as a food for preventing infection, and can also be used as a food or drink for preventing gastritis, gastric ulcer and duodenal ulcer.

[0016]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described below. However, these embodiments are shown as examples, and various modifications can be made without departing from the technical idea of the present invention. Needless to say.

As a specific example of steryl glucopyranoside, cholesteryl-α-D-glucopyranoside (hereinafter referred to as α
-Cholesteryl glucopyranoside or α-CG), cholesteryl-β-D-glucopyranoside (hereinafter β-cholesteryl glucopyranoside or β-CG
Sometimes referred to as), β-sitosteryl-β-D-glucopyranoside (hereinafter sometimes referred to as β-sitosteryl glucopyranoside), stigmasteryl-β-D-
Glucopyranoside (hereinafter sometimes referred to as stigmasteryl glucopyranoside), campesteryl-β-D-
Glucopyranoside (hereinafter sometimes referred to as campesteryl glucopyranoside), and brassicasteryl-β-
D-glucopyranoside (hereinafter sometimes referred to as brassicasteryl glucopyranoside) was used.

Steryl glucopyranoside is a known naturally occurring compound. Cholesteryl glucopyranoside can be obtained as a reagent, an industrial raw material, etc., and in the examples described later, those chemically synthesized by the following method were used. α-CG: CAS registration number: 40653-08-5 β-CG: CAS registration number: 7073-61-2

Β-sitosteryl glucopyranoside, stigmasteryl glucopyranoside, campesteryl glucopyranoside and brassicasteryl glucopyranoside are compounds existing in plants and can be obtained by various methods, but the compounds used in the examples described later are It was obtained by the following method.

Lipids were extracted from dried soybean powder (kinako) using ethanol. The resulting lipid is HPTL
Purification was carried out using a C plate to obtain β-sitosteryl glucopyranoside, stigmasteryl glucopyranoside, campesteryl glucopyranoside and brassicasteryl glucopyranoside. The yields are 0.1% and 0.
It was 03%, 0.04%, and 0.002%. The developing solvent is (chloroform: methanol: water = 70: 30: 4)
It was performed under the conditions of. Each of the obtained compounds was dissolved in ethanol before use.

The anti-Helicobacter pylori agent according to the present invention contains steryl glucopyranoside as an active ingredient, and the addition of steryl glucopyranoside to liquid-cultured Helicobacter pylori dramatically reduces the number of Helicobacter pylori inhabitants. . The amount of steryl glucopyranoside added may be 0.5 to 30 μg / ml, more preferably 1 to 20 μg / ml, and most preferably 5 to 15 μg / ml steryl glucopyranoside. is there. Steris glucopyranoside is a naturally occurring and highly safe compound,
There is no problem even if it is added in a larger amount than the above range, but since the intended antibacterial effect is achieved in the above-mentioned range of addition, the added amount in the above range is preferable from the economical point of view.

Further, the number of times of addition is such that the antibacterial effect is exhibited by one addition, and the number of times is not limited.

The effect of the anti-Helicobacter pylori agent according to the present invention is obtained under acidic conditions (pH as shown in Examples described later).
Also in 5), it has a great antibacterial action against Helicobacter pylori by itself. 1 for antibiotics at this acidity
In view of the fact that the steryl glucopyranoside of the present invention has a great effect by itself, while the anti-bacterial effect is not seen by itself alone, the steryl glucopyranoside in the gastric fluid under the strongly acidic condition of pH 1-2 is considered. The anti-Helicobacter pylori agent containing the active ingredient is expected to have a sufficient bactericidal action.

Further, by using steryl glucopyranoside and an antibiotic together, the antibacterial effect can be further enhanced.

Any antibiotic may be used in combination, as long as Helicobacter is sensitive to it.
It is more preferable. For example, ampicillin, metronidazole, clarithromycin and the like can be used.

The amount of antibiotics added is not limited, and for example, ampicillin, metronidazole and clarithromycin are 0.25 μg / ml and 0.25 μg / m, respectively.
A large antibacterial effect is shown at the addition concentrations of 1 and 4 μg / ml.

The number of antibiotics used in combination is not limited, and a combination of steryl glucopyranoside and one antibiotic has a great antibacterial action, but several antibiotics may be used in combination.

The antibiotics may be added separately from the steryl glucopyranoside or may be added simultaneously.

Up to now, the antibiotic eradication of Helicobacter pylori has required the administration of several antibiotics in combination with PPI. However, by containing an antibiotic in an anti-Helicobacter pylori agent containing the steryl glucopyranoside of the present invention as an active ingredient, it is possible to eradicate Helicobacter pylori without requiring the use of two or more antibiotics or PPI. Become.

Further, the combined use of steryl glucopyranoside and lactic acid can further enhance the antibacterial effect.

The amount of lactic acid added is not limited, and is 1 to 1000.
μg / ml is sufficient, and further 10 to 100 μg / m
1 is preferred.

Lactic acid may be added separately from steryl glucopyranoside or may be added simultaneously.

Up to now, the bactericidal effect of Helicobacter pylori by lactic acid has not been obtained so much under physiological conditions. However, by adding lactic acid to the anti-Helicobacter pylori agent containing the steryl glucopyranoside of the present invention as an active ingredient, it is possible to eradicate Helicobacter pylori using lactic acid even under acidic conditions.

Development of gastritis, gastric ulcer or duodenal ulcer,
Alternatively, the anti-Helicobacter pylori agent according to the present invention can be used as it is as a relapse or relapse inhibitor, or can be used in accordance with a conventional method as appropriate in combination with an ordinary pharmaceutical carrier.

The administration method of the anti-Helicobacter agent according to the present invention is not limited, but oral administration such as tablets, capsules, granules, powders, syrups, fine granules and coated tablets is preferable. The amount of the anti-Helicobacter pylori agent added to the inhibitor may be arbitrary, but may be appropriately determined depending on the use situation, purpose or method, and is not limited, but usually 0.0001 to 10% is suitable. .

As a food or drink for the prevention of gastritis, gastric ulcer or duodenal ulcer, the anti-Helicobacter pylori agent according to the present invention can be used as it is, fermented milk such as yogurt, lactic acid bacterium drink, powdered food, granular food, paste food, etc. It can be appropriately used according to a conventional method by combining it with the food or drink or the ingredients of the food or drink.

The amount of the anti-Helicobacter pylori agent to be added to the food or drink may be arbitrary, but it may be appropriately determined according to the purpose of use, and usually 0.0001 to 10% is suitable.
The steryl glucopyranoside contained as an active ingredient in the anti-Helicobacter pylori agent of the present invention has no safety problem and is therefore particularly suitable for ingestion even when used in combination with food and drink.

[0038]

EXAMPLES Examples of the present invention will be described below, but the present invention is not limited to these examples.

Materials used in Examples of the present invention are as follows.
Is described. (material) As a Helicobacter pylori, H. pylori NCTC 11637
Strains, ATCC 43504 strain and ATCC 43624 strain were used. For liquid culture, add 6% horse serum (HS, Gibco)
Use Brain Heart Infusion Broth (BHIB, Difco)
I was there. Brain Heart In is a plate medium for measuring viable cell count.
7% defibrinated horse in 1.5% agar solution of fusion (BHI)
It was created by adding blood (Japan Biotest Institute). For Helicobacter pylori culture, Aneropack
Using a temperature sensor (Mitsubishi Gas Chemical Co., Ltd.)
Element: oxygen: carbon dioxide = 85: 5: 10) in a container
In, the culture was performed using a closed container. BHIB adjusts the pH using HCl and NaOH.
became. Dissolve each steryl glucopyranoside in ethanol
used. Ampicillin and metronidazole are phosphorus
Acid buffer solution (composition: KCl = 0.2 g / l, KH ₂PO_Four
= 0.2 g / l, NaCl = 8 g / l, Na₂HPO
_Four(Anhydrous) = 1.15 g / l: hereinafter referred to as PBS (-)
It was used after being dissolved. Also, clarithromycin
It was dissolved in chloroform and used.

(Examples 1 to 4 and Comparative Example 1): Antibacterial effect of Helicobacter pylori by addition of α-cholesteryl glucopyranoside (α-CG) (method) BHIB50 containing 6% HS adjusted to pH 5
ml into a 500 ml flask, where the final concentration is 0.5 μg / ml (Example 1), 1.5 μg / ml
(Example 2), 5.0 μg / ml (Example 3) and 1
Α-Cholesteryl glucopyranoside was added so as to be 5.0 μg / ml (Example 4) (not added in Comparative Example 1) and mixed well. 1.4x10 there
H. pylori NCTC 11637 bacterial solution was inoculated to ⁷ CFU / ml and shake culture was carried out at 37 ° C. under microaerobic conditions.

A part of the culture solution was collected 24 hours after the inoculation, and a 10-fold dilution series was prepared using PBS (-). 100 μl of the solution was spread on a plate medium and allowed to stand under microaerobic conditions at 37 ° C., and culture was carried out for 1, 2, 3 and 7 days.

Then, the number of colonies formed was measured,
The viable cell count was calculated based on the value and the dilution ratio.

(Results) FIG. 1 shows the results of the antibacterial effect of α-CG against Helicobacter pylori. α-C
It was found that in the medium to which G was added, one day after inoculation with Helicobacter pylori, a great antibacterial effect was exhibited.

(Example 5): Antibacterial effect of Helicobacter pylori by adding α-cholesteryl glucopyranoside (method) BHIB50 containing 6% HS adjusted to pH 5
ml into a 500 ml flask where the final concentration is 0.5, 1.0, 2.5, 5.0, 7.5, 15.0
α-Cholesteryl glucopyranoside was added to each to give a concentration of μg / ml and mixed well. 1.4x there
Inoculate the bacterial solution to 10 ⁷ CFU / ml and
Shaking culture was performed under microaerobic conditions at ℃.

A part of the culture solution was collected 24 hours after the inoculation, and a 10-fold dilution series was prepared using PBS (-). 100 μl of the solution was spread on a plate medium and allowed to stand under microaerobic conditions at 37 ° C. for 4 to 5 days of culture.

The antibacterial action is based on the standard method (Ch
The minimum inhibitory concentration (MIC) was measured according to emotherapy 29: 76-79, 1981). Regarding the MIC, the lowest concentration at which the growth was completely inhibited was defined as the MIC value.

(Results) Table 1 shows the measurement results of the MIC values. It was found that α-cholesteryl glucopyranoside has antibacterial activity under acidic conditions.

(Example 6): Antibacterial effect of Helicobacter pylori by addition of β-cholesteryl glucopyranoside (Method) By the same procedure and conditions as in Example 5 except that β-cholesteryl glucopyranoside was added instead of α-cholesteryl glucopyranoside. The MIC value was measured.

(Results) Table 1 shows the measurement results of the MIC values. It was found that β-cholesteryl glucopyranoside has antibacterial activity under acidic conditions.

(Example 7): Antibacterial effect of Helicobacter pylori by the addition of β-sitosteryl glucopyranoside (Method) The same procedure as in Example 5 except that β-sitosteryl glucopyranoside was added instead of α-cholesteryl glucopyranoside. The MIC value was measured depending on the conditions.

(Results) Table 1 shows the measurement results of the MIC values. It was found that β-sitosteryl glucopyranoside has antibacterial activity under acidic conditions.

(Example 8): Antibacterial effect of Helicobacter pylori by addition of stigmasteryl glucopyranoside (Method) The same procedure as in Example 5 except that stigmasteryl glucopyranoside was added instead of α-cholesteryl glucopyranoside. The MIC value was measured depending on the conditions.

(Results) Table 1 shows the measurement results of the MIC values. It was found that stigmasteryl glucopyranoside has antibacterial activity under acidic conditions.

(Example 9): Antibacterial effect of Helicobacter pylori by addition of campesteryl glucopyranoside (Method) The same procedure and conditions as in Example 5 except that campesteryl glucopyranoside was added instead of α-cholesteryl glucopyranoside. , Its MIC value was measured.

(Results) Table 1 shows the measurement results of the MIC values. It was found that campesteryl glucopyranoside has antibacterial activity under acidic conditions.

(Example 10): Antibacterial effect of Helicobacter pylori by addition of brassicasteryl glucopyranoside (Method) By the same procedure and conditions as in Example 5 except that brassicasteryl glucopyranoside was added instead of α-cholesteryl glucopyranoside. , Its MIC value was measured.

(Results) Table 1 shows the measurement results of the MIC values. It was found that brassicasteryl glucopyranoside has antibacterial activity under acidic conditions.

[0058]

[Table 1]

(Examples 11 to 15 and Comparative Examples 2 to 6):
Effect of Antibiotics and Lactic Acid on Helicobacter pylori Incorporating α-Cholesteryl Glucopyranoside (Method) BHIB with 6% HS Adjusted to pH 5.0
50 ml was put into a 500 ml flask, and α-cholesteryl glucopyranoside was added thereto so that the final concentration was 5 μg / ml (Examples 11 to 15) (in the case of Comparative Examples 2 to 6, it was not added). , Well mixed. H. so that it would be 1.4 × 10 ⁷ CFU / ml.
A pylori NCTC strain 11637 strain solution was inoculated and shake-cultured at 37 ° C. under microaerobic conditions.

After 3 days, antibiotics [ampicillin (Example 11 and Comparative Example 2), clarithromycin (Example 12 and Comparative Example 3) or metronidazole (Example 13 and Comparative Example 4)] and lactic acid (Example 14 and Comparative Example 5) were added respectively. The final concentrations of ampicillin, clarithromycin, metronidazole, and lactic acid were 0.25 μg / ml and 0.25, respectively.
μg / ml, 4 μg / ml, 5 μg / ml. In addition, a case where neither an antibiotic nor lactic acid was added (Example 15 and Comparative Example 6) was also performed.

A portion was collected 24 hours after the addition of the antibiotic and lactic acid, and a 10-fold dilution series was prepared using PBS (-). 100 μl of this was spread on a plate medium and allowed to stand under microaerobic conditions at 37 ° C., and culture was performed for 4 to 5 days.

Then, the number of colonies formed was measured,
The viable cell count was calculated based on the value and the dilution ratio.

(Results) FIG. 2 shows that α-cholesteryl glucopyranoside was present [FIG. 2 (a)] / absent [FIG.
(B)] shows the effect of antibiotics and lactic acid on Helicobacter pylori when the antibiotics and lactic acid were added. The graphs show the viable cell counts without addition of antibiotics and lactic acid, that is, Example 1 for Examples 11 to 15.
For the viable cell count of 5 and Comparative Examples 2 to 6, the viable cell count of Comparative Example 6 is taken as 100% and is shown as a relative viable cell rate.

When the antibiotics and lactic acid were added, and when the α-cholesteryl glucopyranoside was not incorporated, the addition of the antibiotics and lactic acid showed almost no change in the viable cell ratio. A significant reduction in viability was observed when cholesteryl glucopyranoside was incorporated.

(Comparative Examples 7 to 10): Effect of culture pH and antibiotics on Helicobacter pylori (method) 50 ml of BHIB containing 6% HS adjusted to pH 5.0, 6.0, 7.0 and 8.0, 50 each
Put it in a 0 ml flask, and put 1.4 × 10 ⁷ CFU in it.
H. pylori NCTC 11637 bacterial solution was inoculated so that the concentration became / ml, and shake culture (120 rpm) was carried out under microaerobic conditions at 37 ° C.

Then, 24 hours later, each antibiotic was added. The final concentration was 0.2 for ampicillin (Comparative Example 7) and clarithromycin (Comparative Example 8).
5 μg / ml, metronidazole (Comparative Example 9) 4 μg
/ Ml. Further, the case where no antibiotic was added (Comparative Example 10) was also performed.

A portion was collected 24 hours after the addition of the antibiotic and a 10-fold dilution series was prepared using PBS (-).
100 μl of this was spread on a plate medium and allowed to stand under microaerobic conditions at 37 ° C., and culture was performed for 4 to 5 days.

Then, the number of colonies formed was measured,
The viable cell count was calculated based on the value and the dilution ratio.

(Results) FIG. 3 shows the results of the effect of antibiotics on Helicobacter pylori at each pH.
From the graph, it can be seen that the effect of antibiotics decreases as the acidity increases, and no effect is seen at pH 5.0.

[0070]

As described above, according to the anti-Helicobacter pylori agent containing the steryl glucopyranoside and / or its derivative of the present invention as an active ingredient, a composition having an antibiotic or other bactericidal effect, and gastric acid It is not necessary to use a secretion inhibitor, and it is possible to obtain a great eradication effect against Helicobacter pylori even under physiological conditions (acidic conditions). Further, the combined use of the anti-Helicobacter pylori agent of the present invention with an antibiotic and / or lactic acid makes it possible to further enhance the bactericidal action. In addition, by incorporating the anti-Helicobacter pylori agent of the present invention into a preparation, it can be used as an agent for preventing the onset and recurrence of gastritis, gastric ulcer or duodenal ulcer, and relapse. Furthermore, by including the anti-Helicobacter pylori agent of the present invention in a food or drink, it can be used as a food or drink for preventing gastritis, gastric ulcer or duodenal ulcer.

The steryl glucopyranoside and its derivatives used in the anti-Helicobacter pylori agent of the present invention are natural products and are highly safe, and therefore have extremely excellent usefulness as health foods, food additives, medical drugs and the like. Be expected.

[Brief description of drawings]

FIG. 1 is a graph showing the results of Examples 1 to 4 and Comparative Example 1, in which (a) shows the relationship between the number of culture days and the viable cell count (× 10 ⁸ ) in Examples 1 to 4 and Comparative Example 1. (B) shows the relationship between the number of days of culture and the number of viable bacteria (× 10 ⁴ ) in Examples 1 to 4, respectively.

FIG. 2 is a graph showing the results of Examples 11 to 15 and Comparative Examples 2 to 6, where (a) is the viable cell rate in Examples 11 to 15, and (b) is the viable cell rate in Comparative Examples 2 to 6. Are shown respectively.

FIG. 3 is a graph showing the relationship between pH and viable cell count in Comparative Examples 7 to 10.

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 1/04 A61P 31/04 4C206 31/04 C07J 9/00 C07J 9/00 A23L 2/00 F F term (reference) 4B017 LC03 LK08 LK11 LK30 LL09 4B018 LB08 MD09 MD27 MD94 ME09 4C084 AA16 CA62 MA02 NA05 ZA682 ZB352 4C086 AA01 AA02 EA19 MA01 MA02 MA03 MA04 MA52 NA05 ZA68 ZB35 4C091 AA02 BB01 BB06 CC01 DD01 EE06 FF01 GG01 HH01 JJ01 KK01 LL01 MM01 NN01 PA02 PA05 PB05 QQ01 4C206 AA01 AA02 DA09 MA02 MA03 MA04 NA05 ZA68 ZB35

Claims (6)

[Claims] 1. An anti-Helicobacter pylori agent containing steryl glucopyranoside and / or its derivative as an active ingredient. 2. The steryl glucopyranoside is at least one compound selected from the group consisting of cholesteryl glucopyranoside, sitosteryl glucopyranoside, stigmastereryl glucopyranoside, campesteryl glucopyranoside and brassicasteryl glucopyranoside. The anti-Helicobacter pylori agent according to claim 1. 3. The anti-Helicobacter pylori agent according to claim 1, wherein the derivative is an acylated derivative. 4. The anti-Helicobacter pylori agent according to any one of claims 1 to 3, further comprising an antibiotic and / or lactic acid as an active ingredient. 5. An agent for preventing the onset or recurrence of gastritis, gastric ulcer or duodenal ulcer, and relapse, comprising the anti-Helicobacter pylori agent according to any one of claims 1 to 4. 6. A food or drink for preventing gastritis, gastric ulcer or duodenal ulcer, comprising the anti-Helicobacter pylori agent according to any one of claims 1 to 4.